Bronchogen (20mg) is a synthetic short-peptide research material supplied for controlled laboratory investigation and analytical evaluation. It may be used as a test article in qualified in vitro research involving peptide characterization, biochemical interactions, and respiratory-tissue-derived experimental models.
Bronchogen is supplied as a lyophilized research material. Product identity, analytical results, and applicable testing methods should be confirmed using the lot-specific Certificate of Analysis.
Nordsci Peptides provides batch-specific analytical documentation where available. Researchers should consult the corresponding Certificate of Analysis for the methods performed and results reported for a particular lot.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Bronchogen (20mg) is a synthetic short-peptide research material supplied for controlled laboratory investigation and analytical evaluation. It may be used as a test article in qualified in vitro research involving peptide characterization, biochemical interactions, and respiratory-tissue-derived experimental models.
Bronchogen is supplied as a lyophilized research material. Product identity, analytical results, and applicable testing methods should be confirmed using the lot-specific Certificate of Analysis. This product is not supplied as a drug, dietary supplement, food, cosmetic, medical product, or veterinary product.
Bronchogen (20mg) – Research Specifications:
| Compound | Bronchogen |
| Nominal Quantity | 20mg per vial |
| Compound Type | Synthetic short-peptide research material |
| Molecular Formula | Refer to available technical or batch-specific documentation |
| Molecular Weight | Refer to available technical or batch-specific documentation |
| CAS Number | Not specified; consult available product documentation |
| Sequence | Refer to available technical documentation where provided |
| Form | Lyophilized powder |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis for reported methods and results |
| Storage Conditions | Store sealed in a cool, dry environment away from light, heat, and moisture |
| Intended Use | Laboratory research and analytical evaluation only |
| Restrictions | Not for human or animal consumption or human or veterinary in vivo use |
Bronchogen is identified as a synthetic short-peptide research material. Short peptides may be evaluated in laboratory environments to characterize their physicochemical properties, analytical profiles, and behavior within defined experimental systems.
Published research may discuss Bronchogen in connection with respiratory-tissue-derived models. Such context does not establish that the compound produces a beneficial, protective, restorative, or therapeutic effect in humans or animals. Any proposed biochemical activity must be independently evaluated through appropriately designed laboratory experiments.
Bronchogen may be examined alongside other peptide research materials when laboratories compare analytical methods, assay conditions, or biochemical interactions. Related research materials include BPC 157, Thymosin Beta 4, and GHK-CU. Each compound must be evaluated independently using its corresponding technical documentation and lot-specific analytical records. References to other compounds do not indicate that the materials should be combined or used for any particular outcome.
Important Research Notice: Nordsci research materials are supported by lot-specific analytical documentation where available. Laboratories should review the applicable Certificate of Analysis to verify the tests performed, analytical methods used, and results reported for the supplied batch.
FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR HUMAN OR VETERINARY IN VIVO USE. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Bronchogen may be used as a test article in controlled in vitro experiments involving respiratory epithelial cell models. These studies may measure predefined biochemical markers, assay responses, or peptide-related interactions under documented laboratory conditions. Its inclusion in an assay does not establish respiratory support, protective activity, or suitability for clinical or veterinary use.
Qualified laboratories may evaluate Bronchogen in experimental systems designed to study cellular signaling or assay behavior in airway-tissue-derived models. Researchers should define appropriate controls, endpoints, and acceptance criteria before conducting these experiments. No claim is made that Bronchogen maintains, restores, or otherwise changes airway tissue in humans or animals.
Bronchogen may be included in in vitro assays that measure selected biochemical markers associated with inflammatory signaling. Such experiments are limited to controlled laboratory investigation and do not demonstrate anti-inflammatory activity, immune support, or a therapeutic effect. Results may vary according to the model, assay method, controls, material concentration, environmental conditions, and analytical platform.
In laboratory research, Bronchogen may be evaluated as a test article in assays involving selected cellular pathways within pulmonary-tissue-derived experimental models. These investigations are intended to characterize measurable laboratory responses rather than demonstrate tissue regeneration or repair. No regenerative, restorative, protective, or clinical outcome is represented or implied.
Bronchogen (20mg) should be handled only by qualified personnel using established laboratory procedures for research chemicals and peptide materials. Laboratories should maintain appropriate documentation, contamination controls, environmental controls, and material traceability.
Protocol Design Considerations: Experimental results may be affected by assay type, control selection, sample preparation, environmental conditions, analytical sensitivity, and baseline characteristics of the selected model. Researchers are responsible for developing and validating protocols appropriate to their institution and intended analytical purpose.
No dosing, administration, injection, ingestion, application, or human or animal use instructions are provided.
Note: This information is supplied strictly as a laboratory research reference. It is not medical, veterinary, diagnostic, therapeutic, or consumer-use guidance.
Lot-specific analytical documentation for Bronchogen may be accessed through the Nordsci Peptides COA Library. The applicable Certificate of Analysis should be reviewed to determine the identity or purity methods performed and the results reported for the corresponding batch. A Certificate of Analysis documents specific analytical findings for the tested sample; it does not establish safety, efficacy, clinical suitability, or approval for human or animal use.
Nordsci Peptides supplies Bronchogen (20mg) as a laboratory research material. Laboratories evaluating research-material suppliers should review product identification, batch traceability, storage documentation, analytical methods, and the availability of lot-specific Certificates of Analysis.
IMPORTANT: Bronchogen (20mg) is supplied exclusively for laboratory research and analytical evaluation. It is not a drug, dietary supplement, food, cosmetic, or medical or veterinary product. It is not approved for human consumption, animal consumption, clinical use, veterinary use, diagnostic use, or therapeutic application. Purchasers are responsible for complying with all applicable institutional, local, state, and federal requirements.
